Tuspetinib Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Tuspetinib comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leukemia, Myeloid, Acute. Most recent publication: Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia., Cancer Res Commun, 2025.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.Sonowal H, Rice WG, Bejar R, et al. · Cancer Res Commun · 2025
Publications by year
2025–2025: 1 publications.
2025
1
Publications by indication
Leukemia, Myeloid, Acute (1)
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.
Publications by journal
- Cancer Res Commun1 paper
All Tuspetinib publications (1)
2025 (1 paper)
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.Sonowal H, Rice WG, Bejar R, et al. · Cancer Res Commun · 2025 · Derived
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Tue, 02 Jun 2026 17:46:42 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).